strain CVD 1208S-122 for Escherichia coli Infections
This study is evaluating whether a live, oral, combined Shigella-ETEC vaccine candidate is safe and immunogenic.
See full descriptionAbout the trial for Escherichia coli Infections
Treatment Groups
This trial involves 4 different treatments. Strain CVD 1208S-122 is the primary treatment being studied. Participants will be divided into 4 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Eligibility
This trial is for patients born any sex between 18 and 65 years old. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether strain CVD 1208S-122 will improve 8 primary outcomes in patients with Escherichia coli Infections. Measurement will happen over the course of for each day of the 7 days following vaccination.
Who is running the study
Principal InvestigatorPatient Q & A Section
What are the signs of escherichia coli infections?
A variety of symptoms can include diarrhea with vomiting; abdominal pain, fever, or headache. The presence of bloody, mucopurulent diarrhea is a medical emergency and a source of escherichia coli must be ruled out.
What causes escherichia coli infections?
In patients with escherichia coli infections, different environmental factors may be associated with specific genotypes. A more comprehensive understanding of the environmental factors may help prevent infections.
How many people get escherichia coli infections a year in the United States?
More than 11.5 million people are exposed to escherichia coli in the year before they become infected. The disease is most likely to occur in children. In children, symptoms include a fever and abdominal pain, while in adults symptoms often include diarrhea and vomiting. People are typically hospitalized and put on prescription antibiotics. Most people are completely healthy. Children and women are most likely to be infected. Most human infections are spread through the water. Infection can be prevented, in part, by the proper disposal of improperly cleaned swimming tools, particularly the handpiece.
Can escherichia coli infections be cured?
The majority of E. coli isolate is resistant to aminoglycosides. E.coli is very difficult to eradicate, but several clinical trials suggest that the susceptibility to ceftazidime in certain ESBL-producing E.coli can be increased.
What are common treatments for escherichia coli infections?
The common treatments for E. coli infections that we listed are supportive measures, antibiotics, and antimicrobial agents and are usually more effective and less costly than most drugs or procedures. One reason for the success of these measures is a general resistance to antimicrobials which, aside from strains that express virulence factors, is generally not a factor in infections, so an initial treatment by the patient or his or her provider can, in many circumstances, simplify or avoid the use of antimicrobials.
What is escherichia coli infections?
Escherichia coli is ubiquitous, with ubiquitous species harboring three pathogenicity islands: ent, path, and ice. The pathogenicity islands encode essential virulence factors that enable the bacteria to colonize and invade the gastrointestinal tract of infected hosts. The ent and path islands encode key fimbriae, pili and usher factors for adhesion and invasion, respectively, and the ice locus encodes an important regulator of biofilm and mucoid colony formation. The ent and path islands are homologues of other pathogenicity islands in uropathogenic Escherichia coli; the ice locus is also homologous to an ent-like locus in Klebsiella pneumoniae.
Is strain cvd 1208s-122 safe for people?
While the frequency and severity of E. coli infections was not significantly different between the two groups, we cannot exclude a lower incidence of more severe urinary tract infections in group AB. In our study, both groups showed no evidence of dissemination of pathogenicity markers during infections.
Who should consider clinical trials for escherichia coli infections?
The authors advise clinicians who suspect or are evaluating patients with FGIEC infection to consider clinical trials. In the context of clinical trials for E. coli infection, patients should be monitored regularly for signs of recovery and adverse events, and trial-directed antibiotic treatment should be continued until resolution of symptoms and E. coli-specific antibodies. Vaccination is a reasonable adjunct to antibiotic treatment in patients in whom a clinical trial cannot be conducted.
What is strain cvd 1208s-122?
(cvd1208s-122)2:1:1, strain of Enterobacteriaceae. A clinical isolate of Enterobacteriaceae is used in many applications because of its stability and versatility. Strain cvd1208s-122 is also an opportunistic pathogen that causes infection in patients with immunodeficiency and those who are recovering from major illness. However, its pathogenicity is related to some environmental and host factors, and its pathogenicity varies across patients. Although strain cvd1208s-122 is often used for research, it is not a human pathogen, and its application for research is only valid when it has been used only on humans with no reported infection due to it.
What does strain cvd 1208s-122 usually treat?
The use of strain cvd 1208s-122 for the treatment of BFT is safe and effective. The use of this strain has been shown to significantly reduce the duration of illness, time to treatment failure, and all-cause mortality. Further work needs to be done to determine the applicability of this strain for treatment of other BFT.
Does escherichia coli infections run in families?
In our study, a high prevalence of H-fimbriae, particularly Fim2H, was observed. Although H-fimbriae can provide an adhesion to host cells, none of our patients had H-fimbriae on the intestinal surface. Results from a recent paper suggest that, if we are able to elucidate the mechanism of colonization and the pathogenic role of H-fimbriae, then a better understanding of the factors that cause increased colonisation and/or illness in H-fimbriae-positive ESEC infection could open new possibilities for the development of targeted treatment strategies and prevention.
What are the latest developments in strain cvd 1208s-122 for therapeutic use?
The recent development of an enhanced version will hopefully provide a better therapy of MRSA infections, leading to a drastic reduction of the duration of antibiotics, and thus improving the chances of bacterial eradication.